Megan Hohenberger1, Leah A Cardwell1, Elias Oussedik1, Steven R Feldman1,2,3. 1. a Department of Dermatology, Wake Forest School of Medicine , Center for Dermatology Research , Winston-Salem , NC , USA. 2. b Department of Pathology , Wake Forest School of Medicine , Winston-Salem , NC , USA. 3. c Department of Public Health Sciences , Wake Forest School of Medicine , Winston-Salem , NC , USA.
Abstract
INTRODUCTION: Interleukin 17 (IL-17) antagonism provides a highly effective approach for treating psoriasis. Exacerbations of inflammatory bowel disease have been reported in anti-IL-17 psoriasis trials. AIM: To characterize the relationship between IL-17 inhibition and inflammatory bowel disease. METHODS: A review of English-language articles was performed. Search terms included IL-17, psoriasis, inflammatory bowel disease, secukinumab, ixekizumab and brodalumab. RESULTS: IL-17 A inhibition, IL-17RA inhibition and IL-17 knockout led to induction or exacerbation of colitis in mouse models. The placebo groups fared better than the treatment group in controlled trials of anti-IL-17 antibody and anti-IL-17 receptor for Crohn's disease (CD). A brodalumab study (N = 1576) revealed one reported CD case. An ixekizumab study (N = 3736) evaluating moderate-to-severe psoriasis, four patients reported CD and seven reported UC while ixekizumab every 2 weeks led to a moderate exacerbation of UC in one patient and new-onset CD in one patient. A secukinumab study (N = 3430) revealed exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and UC, respectively. DISCUSSION: Anti-IL-17 medications are associated with IBD exacerbation. Caution should be used in prescribing these medications in patients with diagnosed IBD or personal history suggestive of IBD.
INTRODUCTION:Interleukin 17 (IL-17) antagonism provides a highly effective approach for treating psoriasis. Exacerbations of inflammatory bowel disease have been reported in anti-IL-17psoriasis trials. AIM: To characterize the relationship between IL-17 inhibition and inflammatory bowel disease. METHODS: A review of English-language articles was performed. Search terms included IL-17, psoriasis, inflammatory bowel disease, secukinumab, ixekizumab and brodalumab. RESULTS:IL-17 A inhibition, IL-17RA inhibition and IL-17 knockout led to induction or exacerbation of colitis in mouse models. The placebo groups fared better than the treatment group in controlled trials of anti-IL-17 antibody and anti-IL-17 receptor for Crohn's disease (CD). A brodalumab study (N = 1576) revealed one reported CD case. An ixekizumab study (N = 3736) evaluating moderate-to-severe psoriasis, four patients reported CD and seven reported UC while ixekizumab every 2 weeks led to a moderate exacerbation of UC in one patient and new-onset CD in one patient. A secukinumab study (N = 3430) revealed exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and UC, respectively. DISCUSSION: Anti-IL-17 medications are associated with IBD exacerbation. Caution should be used in prescribing these medications in patients with diagnosed IBD or personal history suggestive of IBD.
Authors: Thomas Greuter; Florian Rieder; Torsten Kucharzik; Laurent Peyrin-Biroulet; Alain M Schoepfer; David T Rubin; Stephan R Vavricka Journal: Gut Date: 2020-08-26 Impact factor: 31.793
Authors: Johan Burisch; Wolfgang Eigner; Stefan Schreiber; Daniel Aletaha; Wolfgang Weninger; Michael Trauner; Walter Reinisch; Neeraj Narula Journal: PLoS One Date: 2020-05-27 Impact factor: 3.240
Authors: Stefan Schreiber; Jean-Frederic Colombel; Brian G Feagan; Kristian Reich; Atul A Deodhar; Iain B McInnes; Brian Porter; Ayan Das Gupta; Luminita Pricop; Todd Fox Journal: Ann Rheum Dis Date: 2019-01-23 Impact factor: 19.103
Authors: J L W Lambert; S Segaert; P D Ghislain; T Hillary; A Nikkels; F Willaert; J Lambert; R Speeckaert Journal: J Eur Acad Dermatol Venereol Date: 2020-08-13 Impact factor: 6.166